Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

Author:

Sodhi Mohit1,Rezaeianzadeh Ramin1,Kezouh Abbas2,Etminan Mahyar3

Affiliation:

1. Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

2. StatExpert Ltd, Laval, Quebec, Canada

3. Department of Ophthalmology and Visual Sciences and Medicine, University of British Columbia, Vancouver, Canada

Abstract

This database study examines the association between glucagon-like peptide 1 agonists (eg, semaglutide, liraglutide) used for weight loss and reports of gastrointestinal adverse events.

Publisher

American Medical Association (AMA)

Subject

General Medicine

Reference6 articles.

1. Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice.;Sauer;Horm Metab Res,2015

2. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial.;Rubino;JAMA,2022

3. Glucagonlike peptide 1–based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.;Singh;JAMA Intern Med,2013

4. Incretin-based drugs and intestinal obstruction: a pharmacovigilance study.;Gudin;Therapie,2020

5. Medication-induced gastroparesis: a case report.;Kalas;J Investig Med High Impact Case Rep,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3